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ABSTRACT
Bacterial DNA gyrase and topoisomerase IV are
selective targets of fluoroquinolones. Topoisom-
erase IV versus gyrase and Gram-positive versus
Gram-negative behavior was studied based on the
different recognition of DNA sequences by topo-
isomerase–quinolone complexes. A careful statisti-
cal analysis of preferred bases was performed on a
large number (>400) of cleavage sites. We found
discrete preferred sequences that were similar
when using different enzymes (i.e. gyrase and
topoisomerase IV) from the same bacterial source,
but in part diverse when employing enzymes from
different origins (i.e. Escherichia coli and Strepto-
coccus pneumoniae). Subsequent analysis on the
wild-type and mutated consensus sequences
showed that: (i) Gn/Cn-rich sequences at and
around the cleavage site are hot spots for quino-
lone-mediated strand breaks, especially for E. coli
topoisomerases: we elucidated positions required
for quinolone and enzyme recognition; (ii) for S.
pneumoniae enzymes only, A and T at positions 2
and +6 are discriminating cleavage determinants;
(iii) symmetry of the target sequence is a key trait to
promote cleavage and (iv) the consensus sequence
adopts a heteronomous A/B conformation, which
may trigger DNA processing by the enzyme–drug
complex.
INTRODUCTION
Type II topoisomerases are ubiquitous ATP-dependent
enzymes that catalyze the transport of one DNA
segment through a transient double-stranded break in
a second segment (1–3). Their role in the cell is to control
the supercoiling of DNA and to untangle the catenanes
that arise during replication or recombination (4–7).
Bacteria express two type IIA topoisomerases, DNA
gyrase (Gyr) and DNA topoisomerase IV (Topo IV) with
distinct and unique functions (1,8). Gyr introduces
negative supercoils into DNA, maintaining bacterial
chromosomes in an underwound state to promote compac-
tion and unwinding (9,10). In contrast, Topo IV is an
eﬃcient decatenase, separating tangled daughter chromo-
somes following replication (11–13). Both Gyr and Topo
IV are heterotetramers, comprising two subunits each of
GyrA and GyrB, and ParC and ParE, respectively (14).
The GyrA and ParC subunits are homologous in their
N-terminal domain that carries the DNA breakage-
reunion function, but diverge in their C-terminal regions
that also contribute to DNA binding (1). The GyrB and
ParE proteins contain the ATPase site involved in energy
transduction and are closely homologous, in both primary
sequence and structure.
Transient double-stranded DNA breakage by Gyr and
Topo IV proceeds via an enzyme–DNA intermediate
termed the ‘cleavage complex’ involving a 4-bp staggered
break and covalent attachment of GyrA or ParC subunits
to each 5-prime (50) DNA-end through a phosphotyrosine
linkage (3,14). Protein–DNA linkage preserves the energy
of the DNA phosphodiester bond and allows resealing
of the DNA backbone by attack of the 3-prime (30)
OH-ends of the broken DNA. The breakage-reunion
equilibrium is overwhelmingly in favor of the intact nucleic
acid chain to avoid fortuitous lethal events in vivo.
However, the cleavage complex can be stabilized by drugs
such as quinolones producing DNA breaks, which can
be detected after enzyme denaturation with sodium dodecyl
sulfate. Generally, DNA cleavage is sequence-selective
and is characterized by covalent bonding of the nucleic
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acid to GyrA or ParC (14–18). Identiﬁcation of DNA
breakage site speciﬁcity is important for the physiological
functions of bacterial topoisomerases and for their roles as
quinolone targets.
Cleavage determinants have been recently determined
for Gyr and Topo IV from a Gram-positive bacterial
species, Streptococcus pneumoniae, in the presence of
various clinically relevant quinolones (19). The cleavage
consensus sequences were GN4G(G/c)(A/c)G
GNNCtTN
(C/a) for Gyr and G(G/c)(A/t)aGNNCt(T/a)N(C/a) for
Topo IV (where the asterisk denotes the cleavage site,
capital letter indicates preferred base, lower case letter
denotes unfavored base and N indicates no base
preference). Similar cleavage preferences were observed
among the quinolones tested. Even though the analysis
was extremely comprehensive, some aspects remain to
be answered (19): (i) The consensus sequence obtained
with both enzymes is strikingly symmetric: does this
property derive from actual enzyme requirements or does
it arise from asymmetric sites as a consequence of
analyzing just one strand of the double helix? (ii) Base
prevalence was analyzed independently at each position:
we do not know yet if the full consensus sequence is
required for eﬃcient DNA cleavage or if only part of it
is necessary. (iii) If the entire consensus sequence, which
spans a 12-base-long DNA tract, is needed for eﬃcient
DNA processing, this relatively long DNA segment
should be statistically represented. Statistical analysis
would hence beneﬁt from using a more assorted
DNA template repertoire.
For Gram-negative bacteria, site-speciﬁc DNA break-
age details are much less exhaustive. Even for Escherichia
coli topoisomerases, the data are scattered and discordant;
for Gyr the most extensive analysis to date involved only
19 sites induced in E. coli on plasmid pBR322 and
generated a 20-bp consensus (20–22); for Topo IV just one
study has been performed, which mapped a weak 2-bp
consensus (15).
This study aimed to address the following points: (i)
investigation and comparison of the cleavage consensus
sequence exhibited by topoisomerases IIA from Gram-
positive (S. pneumoniae) and -negative species (E. coli) on
a large selection of DNA templates; (ii) comparison
of cleavage sites generated by Gyr and Topo IV enzymes;
(iii) assessment of the minimal sequence requirements and
(iv) symmetric/asymmetric properties for eﬀective DNA
recognition and scission by bacterial topoisomerases in the
presence of quinolones.
We found discrete preferred sequences for each enzyme
analyzed. In particular, consensus sequences were very
similar when comparing diﬀerent enzymes (i.e. Gyr and
Topo IV) from the same bacterial source, but partly
diﬀerent using enzymes from diverse origins (i.e. E. coli
and S. pneumoniae). The chemical nature of the ﬂuoro-
quinolones used to stabilize the DNA/enzyme complex in
each case did not play a signiﬁcant role. We proved that
symmetry was a crucial property of the recognized DNA
sequence and that an extended Gn/Cn-rich sequence
improved eﬃcient DNA processing. Speciﬁc bases
inside the 4-bp staggered break were required, possibly
because of their interaction with quinolones, however,
an important role in enzyme recognition was also played
by bases outside the enzymatic cleavage site, Finally, we
provided evidence that the peculiar consensus sequence
suggested by our study adopts an unusual double-
stranded DNA conformation which could trigger
enzyme-DNA recognition.
MATERIALS AND METHODS
Chemicals and reagents
Ciproﬂoxacin and Gemiﬂoxacin were provided by
GlaxoSmithKline (Verona, Italy). Stock solutions were
made in mQ-grade water and diluted to the working
concentration in the desired buﬀer. Buﬀer components
were purchased from Sigma-Aldrich (St. Louis, MO,
USA). Electrophoretic reagents, dNTPs and Taq poly-
merase were from Amersham Biosciences Europe
(Freiburg, Germany). [g-32P]ATP was from Perkin
Elmer (MA, USA); T4 polynucleotide kinase and DNA
ligase were purchased from Invitrogen (Paisley, UK).
Restriction enzymes were purchased from New England
Biolabs (MA, USA).
Topoisomerase enzymes
Topo IV and Gyr from S. pneumoniae were puriﬁed as
previously described (19,23,24). Topo IV and gyrase from
E. coli were puriﬁed as described in (25,26).
DNAs
Plasmid pBluescript II KS(+) and SV40 DNA were
purchased from MBI Fermentas (MD, USA) and
Invitrogen (Paisley, UK), respectively. Primers were
purchased from Eurogentec (Liege, Belgium). Primers
for sequencing analysis used to amplify 239-bp PCR
fragments on SV40 DNA template are described in (23).
The ampliﬁed fragments encompass 27% of the
complete SV40 sequence. Consensus oligos cloned in
pBluescript II KS(+) are: AGGG SYM F: 50-GCC GGG
ATC CTT ACT TCA TGA ATT ATA GGG CCC TGA
TAA TAC CTT AAG AAT TCG CGC-30 and its
complementary (AGGG SYM R); AGGG N-SYM F:
50-GCC GGG ATC CTT ACT TCA TGA ATT ATA
GGG TGT AGA TAA TAC CTT AAG AAT TCG
CGC-30 and its complementary (AGGG N-SYM R);
GGAGGG F: 50-GCC GGG ATC CTT ACT TCA TGA
ATT GGA GGG CCC TCC TAA TAC CTT AAG AAT
TCG CGC-30 and its complementary (GGAGGG R);
GGATGG F: 50-GCC GGG ATC CTT ACT TCA TGA
ATT GGA TGG CCA TCC TAA TAC CTT AAG AAT
TCG CGC-30 and its complementary (GGATGG R);
GGAGTG F: 50-GCC GGG ATC CTT ACT TCA TGA
ATT GGA GTG CAC TCC TAA TAC CTT AAG AAT
TCG CGC-30 and its complementary (GGAGTG R);
GGAGGT F: 50-GCC GGG ATC CTT ACT TCA TGA
ATT GGA GGT ACC TCC TAA TAC CTT AAG AAT
TCG CGC-30 and its complementary (GGAGGT R).
Consensus sequences are underlined.
Primer sequences used to amplify a 215-bp PCR
fragment on each p(consensus oligo) Bluescript II KS(+)
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DNA template are as follows: prBSF 50-GTAA TACGA
CTCACTATAGGGC-30 and prBSR 50-GACCA TGA
TTACGCCAAGCG-30. Consensus sequence oligos used
for CD experiments are: reference: 50-GGGGCCCC-30;
sample1: 50-GGAGGGCCCTCC-30; sample2: 50-ATA
GGGCCCTAT-30; control: 50-GCGACGCGTCGC-30.
Cloning
All consensus sequence oligos (57 bp) contained BamHI
and EcoRI restriction sites at their 50- and 30-end,
respectively, for insertion into EcoRI- and BamHI-cut
pBluescript II KS(+). Consensus oligos contained an
additional AﬂII site ﬂanking the 30-end of BamHI site
to facilitate screening of mutant colonies. Restricted oligos
and plasmid were puriﬁed with Nucleotide Removal
kit and Gel Extraction kit (Qiagen, CA, USA), respec-
tively, and ligated at 168C overnight. Ligation mixtures
were transformed into competent E. coli DH5a cells.
Bacteria were grown in the presence of IPTG and X-Gal,
and white colonies were selected to conﬁrm the presence
of plasmid with the inserted oligo of interest [p(consensus
oligo)Bluescript II KS(+)].
5’-end labeling of primers and PCR reaction
For primer labeling, 100 pmol of primer were incubated
with 2 ml (10 mCi/ml) of [g-32P]ATP and 10 units of
T4 polynucleotide kinase in 50mM Tris–HCl (pH 7.5),
7mM MgCl2 and 10mM DTT, at 378C for 30min. After
incubation, DNA was puriﬁed through MicroSpin G-25
columns (Amersham Biosciences Europe). The labeled
primers were used in PCR to amplify 239- or 215-bp
fragments of SV40 or each p(consensus oligo)Bluescript II
KS(+), respectively. Each PCR reaction was prepared
by mixing 200mM dNTPs, the labeled primer, 100 pmol
of the cold primer, 50 ng of template DNA and 5 units of
Taq polymerase in PCR reaction buﬀer [10mM Tris–HCl
(pH 9.0), 50mM KCl and 1.5mM MgCl2] to a ﬁnal
volume of 100 ml. PCR cycles for both SV40 and
p(consensus oligo)Bluescript II KS(+) templates were
948C for 30 s, 558C for 30 s and 728C for 30 s (30 cycles).
DNA fragments were then puriﬁed with a QIAquick PCR
puriﬁcation kit (Qiagen, CA, USA).
Topoisomerase cleavage assays
Topo IV from S. pneumoniae was reconstituted with
0.45 mg ParC and 1.7mg ParE in reaction buﬀer [40mM
Tris–HCl (pH 7.5), 6mM MgCl2, 10mM DTT, 200mM
potassium glutamate, 50 mg/ml bovine serum albumin
(BSA)]. Reaction buﬀer for Gyr from S. pneumoniae (1U/
ml) was 35mM Tris–HCl (pH 7.5), 24mM KCl, 4mM
MgCl2, 2mM DTT, 6.5% glycerol, 0.1mg/ml BSA. Topo
IV from E. coli was diluted to a ﬁnal concentration
of 0.22mg/ml ParC and 0.44mg/ml ParE in dilution
buﬀer [50mM Tris–HCl, pH 7.5, 150mM NaCl, 1mM
DTT, 40% (w/v) glycerol, 1mM EDTA]. Reaction buﬀer
consisted of 40mM Tris–HCl, pH 7.5, 20mM KCl, 6mM
MgCl2, 1mM DTT, 10mM spermidine, 0.5mg/ml
BSA. Gyr from E. coli was diluted to 0.35mM (0.1U/ml)
in dilution buﬀer [50mM Tris–HCl (pH 7.5), 100mM
KCl, 2mM DTT, 50% glycerol, 1mM EDTA].
Reaction buﬀer consisted of 7mM Tris–HCl
(pH 7.5), 5mM KCl, 0.8mM MgCl2, 0.4mM DTT,
1.3% (w/v) glycerol, 0.1mg/ml BSA. One unit of Gyr is
deﬁned as the amount of enzyme that supercoils 0.5 mg of
relaxed pBR322 DNA in 30min at 378C; one unit of Topo
IV is the amount of enzyme that relaxes 0.4 mg of
supercoiled pBR322 DNA in 30min at 378C.
For DNA cleavage assays, reconstituted topoisomerase
enzymes were incubated with labeled PCR product DNA
in 25 ml reaction mixtures in the presence of diﬀerent drug
concentrations. After a 30-min incubation at 378C, 1 ml
of 10% SDS and 2 ml of a 20mg/ml stock of proteinase
K were added, and incubation continued for 30min at
458C. Samples were precipitated with ethanol, resus-
pended in formamide gel loading buﬀer [95% formamide,
200mM EDTA pH 8.0, 0.1% (w/v) xylene cyanol and
0.1% (w/v) bromophenol blue] and heated at 908C for
2min. Cleavage products were resolved in 8% polyacry-
lamide, 7M urea gels, alongside DNA markers obtained
with the dideoxynucleotide chain termination protocol.
Brieﬂy, G, C, A and T dideoxy-nucleotide ladders were
obtained by incubating 1 ml of labeled primer, 4 ml of
ddNTP/dNTPs extension/termination mixture (27), 50 ng
template DNA, 50mM KCl, 1.5mM MgCl2, 10mM
Tris–HCl (pH 7.5), 5 U Taq DNA polymerase in a
volume of 10 ml at 958C for 30 s, 548C for 30 s, 728C for
1min for 25 cycles and at 958C for 30 s, 728C for 2min
for 10 cycles. Reactions were puriﬁed by ethanol
precipitation. Gels were then transferred to Whatman
3MM ﬁlter paper, dried under vacuum at 808C, and
bands were visualized by phosphorimaging analysis
(Molecular Dynamics, Amersham Biosciences Europe).
Quantiﬁcation was performed by ImageQuant software
(Molecular Dynamics). Each cleavage site was quantiﬁed
as the ratio of the intensity of the cleavage band over
the intensity of the corresponding band/position in the
control lane (enzyme without drug) (intensity ratio= IR).
Only sites with IR > 40 were considered in the statistical
analysis.
Statistical tests
The probability (P) of deviation from expectation of each
nucleotide at each position around the cleavage site
(positions 20/+20) was calculated as previously
described in (23,28).
Circular dichroism
Reference, sample1, sample2 and control oligos were
dissolved in 10mM Na.Cacodylate (29) to a ﬁnal
concentration of 90 mM per residue. Circular dichroism
spectra from 220 to 320 nm were recorded at 48C using
10mm path length cells on a Jasco J810 spectropolari-
meter equipped with a NESLAB temperature controller
and interfaced to a PC100. Observed ellipticities were
converted to mean residue ellipticity [y]=deg cm2dmol1
(Molar Ellipticity).
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RESULTS
Statistical analysis of DNA cleavage sites induced by
quinolone–prokaryotic topoisomerase complexes reveals
discrete consensus sequences
To analyze and compare DNA sequence determinants
of ﬂuoroquinolones and prokaryotic topoisomerase
complexes, we used (i) two clinically approved ﬂuoroqui-
nolones, i.e. ciproﬂoxacin and gemiﬂoxacin (Figure 1).
Ciproﬂoxacin, a second-generation ﬂuoroquinolone, was
used as a reference compound with assessed activity
against Gram-negative and -positive bacteria;
gemiﬂoxacin was included as a new IIIb generation
ﬂuoroquinolone with increased activity against Gram-
positive species. (ii) Both Gyr and Topo IV from E. coli
and S. pneumoniae were employed as representative
of Gram-negative and -positive species, respectively.
(iii) SV40 DNA was used as a generic nucleic acid
template to avoid bias in species-speciﬁc enzyme/DNA
recognition.
Six 239-bp long SV40 segments were 50-end 32P-labeled
and ampliﬁed by PCR reaction to obtain signiﬁcant
coverage of the whole SV40 sequence and processing of a
total of 1434 bp. The forward or reverse strand were
labeled and analyzed independently to gain information
on the symmetry of enzyme-mediated DNA cleavage. All
DNAs were incubated with E. coli- or S. pneumoniae-
derived Gyr or Topo IV in the presence of ciproﬂoxacin or
gemiﬂoxacin, and the cleavage patterns were analyzed by
loading reaction mixtures on denaturing urea-polyacryl-
amide gels to separate DNA fragments (Figure 2A).
For each enzyme/drug combination, we were able to
collect an adequate amount of cleavage sites (i.e. around
30–50 per each strand). Site number was similar between
ciproﬂoxacin and gemiﬂoxacin with E. coli enzymes, while
it was in favor of gemiﬂoxacin with S. pneumoniae
proteins. Sequences of cleavage sites were aligned at the
point of the phosphodiester bond break in the 50 ! 30
orientation, and bases immediately 50 and 30 to the cut
were numbered 1 and +1, respectively.
The deviation of base distribution from the expected
SV40 DNA base frequencies was evaluated at each
position (20 from the cleavage site) by 2 analysis: a
core region of non-random base composition was
found between positions 4 and +8. Probabilities of the
observed base frequency deviations from expectation at
each position were assessed for all cleavage sites on the
forward strand, and non-complementary sites on the
reverse strand, and vice versa, for each enzyme/drug
combination (statistical analysis for Topo IV/ciproﬂox-
acin from E. coli and Gyr/gemiﬂoxacin from S. pneumo-
niae, positions 4/+8, are reported in Figure 2B and C, as
examples). The complete list of favored and disfavored
bases (LogP > 2 and LogP < 2, respectively) is
reported in Table 1.
For the E. coli enzymes, a strong and consistent
preference was observed for positions 1G, +1G,
+2G, +3C, +5C (Table 1). Position +4 also exhibited
a consistent preference for C (6 out of 8 enzyme/drug/
DNA strand combinations), but with a slightly
lower statistical signiﬁcance (1.5 < LogP < 2).
Positions 2/4 and +6/+8 indicated a very mild
preference for G and C, respectively (0.5 < LogP
< 1.5). No essential cleavage diﬀerences were found
between ciproﬂoxacin and gemiﬂoxacin. As for the two
enzymes, the requirements for Topo IV appeared to be
somewhat more stringent than for Gyr, especially for
positions 1 and +5. Positions outside the 4/+8
interval did not show distinct preferences. Disfavored
bases were much less regularly repeated: inside the 4-bp
staggered break only position +2A showed an indication
of non-preference (Table 1).
A thorough statistical analysis for the S. pneumoniae
enzymes has already been reported by Leo et al. (19).
Nonetheless, we performed cleavage analysis on SV40
DNA substrate to: (i) compare results obtained with
S. pneumoniae and E. coli enzymes using the same drugs
and DNA template, (ii) compare results with the same
enzymes on diﬀerent DNA templates [i.e. SV40 and
S. pneumoniae genome (19)] and (iii) address the issue of
consensus sequence symmetry by analyzing both cut DNA
strands. Only one drug was tested with each enzyme
(ciproﬂoxacin with Topo IV and gemiﬂoxacin with Gyr)
because it had already been shown that ﬂuoroquinolone
identity does not play a critical role in DNA recognition
(19). In accordance with the previous analysis (which used
LogP > 3 and LogP < 3 as signiﬁcant), we found
that highly preferred bases for both Topo IV and Gyr
were 2A and +6T; +1G and +4C, and 1G (gyrase
only) were also signiﬁcantly represented. In addition,
+3C and +5C were favored (at LogP > 2) (Table 1).
No steady preference was observed for other positions,
even though positions 4, 3 and +7, +8 showed a mild
inclination for G and C, respectively (0.5 < LogP < 1.5).
Non-preference data were again less stringent: consistency
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Figure 1. Chemical structures of ciproﬂoxacin and gemiﬂoxacin.
Numbering of the ﬂuoroquinolone ring system is shown for ciproﬂoxacin.
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and signiﬁcant –LogP values (LogP < 2) were found
just for –2T and +6A (Table 1).
By collecting data on both forward and reverse DNA
strands, we were able to diﬀerentiate complementary and
non-complementary sites. Analysis of just non-comple-
mentary sites should clarify if DNA symmetry is a
requirement for enzyme recognition. Indeed, symmetry
was maintained for most positions in this set of data
−2
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6
−4 −3 −2 −1 1 2 3 4 5 6 7 8
Position to cleavage site (−1)
−4 −3 −2 −1 1 2 3 4 5 6 7 8
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A
Figure 2. Sequence analysis of ﬂuoroquinolone-stimulated DNA cleavage by Topo IV and Gyr from E. coli and S. pneumoniae. (A) Example of
sequencing gel. A 239-bp SV40 DNA fragment, labeled with 32P at one 50 end, was incubated with E. coli Gyr (GyrEC) and ﬂuoroquinolones.
reaction mixtures were loaded and run on a denaturing urea–8% polyacrylamide gel. DNA fragments were visualized by phosphorimaging. Lanes 3
and 4 are treated with ciproﬂoxacin (C) (25 mM) and gemiﬂoxacin (G) (25mM), respectively. Lanes 1 and 2 are controls for non-treated DNA and
DNA incubated with the enzyme without drugs. Lanes a, c, g, t are marker lanes (M) obtained by the dideoxynucleotide chain termination method.
(B and C) Probabilities of the observed base frequency deviations from expectation at positions 4/+8 observed (B) for Topo IV from E. coli and
ciproﬂoxacin-mediated DNA cleavage or (C) for Gyr from S. pneumoniae and gemiﬂoxacin-mediated DNA cleavage. Position –1 indicates the base 50
of the cleaved phosphodiester bond identiﬁed in sequencing gels. In the ordinate, P is the probability of observing that deviation or more, as either
an excess (above base line) or deﬁcit (below base line) relative to the expected frequency of each base. The expected frequencies were calculated on
416 sites using the overall base frequency of SV40 DNA (G=C=20.4%; A=T=29.6%).
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(data not shown). In particular, the most symmetrically
conserved positions were 1 and +5, and +2 and +3.
Symmetry is required for efficient cleavage at the DNA
consensus sequence
Our statistical analysis indicated a clear-cut consensus
sequence that was in part diﬀerent between E. coli- and
S. pneumoniae-derived enzymes. In particular, GGGCCC
sequence at the 1/+5 interval was obtained with the
Gram-negative enzymes, with enhanced preference for
positions 1 and +5, +2 and +3. On the opposite,
the most preferred bases with S. pneumoniae proteins were
2A and +6T. Positions –1/+5 were GGGCCC as with
E. coli topoisomerases, but this preference was less
statistically represented. In neither case, a major diﬀerence
was noticed between Topo IV and Gyr or between
ciproﬂoxacin and gemiﬂoxacin.
Since these data were obtained independently at each
position, we did not know if the full consensus sequence or
any other base combination was in fact required for
eﬃcient topoisomerase/ﬂuoroquinolone DNA processing.
Further, based on the indication that symmetry aﬀorded
eﬃcient DNA cleavage even at non-complementary sites,
we wanted to verify to what extent this condition aﬀected
enzyme/drug activity on the nucleic acid.
To answer these questions, we focused on the E. coli
enzymes and their preferred sequences: we cloned the 1/
+5 GGGCCC consensus sequence into a plasmid vector
and subsequently ampliﬁed a 215-bp DNA fragment
by PCR. Sequences upstream (8/2) and downstream
(+6/+13) the consensus sequence were arbitrary chosen
to be A/T rich (see Materials and Methods section). A 215-
base long nucleic acid was employed to achieve optimal
topoisomerase processivity: in fact DNAGyr is reported to
protect as much as 150 bp on binding to DNA (16,17).
To test for symmetry, a non-symmetric sequence was
assayed, which maintained only positions 1, +1 and +2
with reference to the established consensus sequence
(i.e. GGGTGT).
Cleavage analysis was performed on the symmetric and
non-symmetric sequences in the presence of E. coli Topo
IV or Gyr and ciproﬂoxacin or gemiﬂoxacin. Data for the
E. coli Topo IV/ciproﬂoxacin combination are shown in
Figure 3. Cleavage was indeed obtained corresponding to
1G of the inserted consensus sequences in the symmetric
oligonucleotide (lane 3, AGGG SYM oligo, Figure 3),
but this was relatively mild compared to cleavage sites on
other portions of the tested sequence. In contrast,
no cleavage was observed at 1G in the non-symmetric
consensus sequence (lane 3, AGGG N-SYM, Figure 3).
It should be noted that all cleavage bands were shared
between the symmetric and non-symmetric DNA. Similar
results were gained with the remaining enzyme/drug
patterns (data not shown).
Determinants of quinolone-induced E. coli
topoisomerase-mediated DNA cleavage
While it is now clear that symmetry is crucial to improve
topoisomerase/ﬂuoroquinolone-mediated DNA cleavage,
the GGGCCC consensus sequence did not stand out as a
hot spot for induced DNA scission. The consensus
sequence found in the present study was limited to
positions between 1 and +5, and the region just outside
this interval (i.e. 8/2 and +6/+13) was arbitrary
chosen to be extremely A/T rich (14 out of 15 bases were
A or T, see Materials and Methods section) in the DNA
oligonucleotide used for the cleavage assay. We hypothe-
sized that these ﬂanking non-random regions could
decrease the cleavage eﬃciency of the consensus sequence.
In fact, our current statistical analysis on both E. coli and
S. pneumoniae topoisomerases showed a preference for
4G, 3G, 2A/G, +6T/C, +7C, +8C, which was not
considered before because at a low statistical signiﬁcance
(i.e. LogP < 2) (Figure 2B and C). In addition, it had
previously been demonstrated that S. pneumoniae enzymes
tested on a diﬀerent DNA template (19), preferred G/C-
rich tracts outside the cleavage site (positions 4, 3 and
+8). We hence introduced this additional information
Table 1. Summary of favored and non-favored bases obtained by statistical analysis of cleavage sites with Topo IV and Gyr from E. coli (Ec) and
S. pneumoniae (Sp) and ciproﬂoxacin (Cipro) or Gemiﬂoxacin (Gemi) quinolones on DNA alternatively labeled on the forward (F) or reverse
(R) strand
Species Enzyme Drug DNA strand Position with respect to cleavage site (1)
4 3 2 1 +1 +2 +3 +4 +5 +6 +7 +8
Ec Topo IV Cipro F Gc G G C C
R G Ga C Cg Ct
Ec Topo IV Gemi F G G Ga Ga Ct Ct
R G G G G Ga C C C g a
Ec Gyr Cipro F G G G C
R G Gt C C
Ec Gyr Gemi F G G C
R G C C
Sp Topo IV Cipro F A A A G C C C Ta C
R A G C Ta
Sp Gyr Gemi F At G G G C C T
R At G C C C T
Preferred and non-preferred bases were selected based on their –LogP value (>2 and <2, respectively). Preferred bases are shown in capital letters
and non-preferred bases are shown in lowercase letters.
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in our current consensus sequence, obtaining the
GGAGGGCCCTCC DNA stretch (named GGAGGG
oligo) spanning positions 4/+8.
Further, to investigate the relative importance of each
position from1 to+2 (and symmetric bases accordingly)
we systematically and independently substituted G with T
from 1 to +1 (and consequently C with A from +3 to
+5), obtaining the following modiﬁed consensus
sequences: GGATGGCCATCC (named GGATGG),
GGAGTGCACTCC (named GGAGTG), GGAGGTA
CCTCC (named GGAGGT).
The new four extended and modiﬁed consensus oligo-
nucleotides were inserted into plasmid vectors, ampliﬁed to
obtain 215 bp DNA tracts and processed as described
above. It should be noted that DNA tracts outside
positions 4 and +8 remained unchanged compared to
the previous AGGG SYM oligo. Cleavage experiments
with E. coli Topo IV and Gyr are shown in Figure 4A and
B, respectively.
1 2 3 a t g c 1 2 3 a t g c
D D D M D D D M
AGGG SYM AGGG N-SYM
Figure 3. Sequence analysis of topoisomerase/ﬂuoroquinolone-mediated
DNA cleavage on the symmetric (AGGGCCCT) and non-symmetric
(AGGGTGTA) consensus sequences. A 215 bp DNA fragment contain-
ing the consensus sequences of interest was labeled with 32P at one 50 end,
and incubated with Topo IV from E. coli in the presence of ciproﬂoxacin
(C). Reaction mixtures were loaded and run on a denaturing urea–8%
polyacrylamide gel. Lanes 3 are treated with ciproﬂoxacin, respectively.
Lanes 1 are controls for non-treated DNA; lanes 2 are controls for DNA
incubated with the enzyme without drugs. Lanes a, t, g and c are marker
lanes obtained by the dideoxynucleotide chain termination method.
1 2 3 4 a t g c 1 2 3 4 a t g c 1 2 3 4 a t g c 1 2 3 4 a t g c
D D C G D D C G D D C G D D C G
Topo IV Topo IV Topo IV Topo IV
GGATGG
M M M M
G
G
A
G
G
G
*
*
*
÷
÷
GGAGGG GGAGGT GGAGTG
1 2 3 4 a t g c 1 2 3 4 a t g c 1 2 3 4 a t g c 1 2 3 4 a t g c
D D C G D D C G D D C G D D C G
Gyr Gyr Gyr Gyr
M M M M
GGATGG
G
G
A
G
G
G
GGAGGG GGAGGT GGAGTG
A
B
Figure 4. Sequence analysis of topoisomerase/ﬂuoroquinolone-
mediated DNA cleavage on the extended and modiﬁed symmetric
consensus sequences (GGA(GorT)(GorT)(GorT)(CorA)(CorA)(CorA)
TCC). A 215-bp DNA fragment containing the consensus sequences
of interest was labeled with 32P at one 50 end, and incubated with Topo
IV (A) or Gyr (B) from E. coli in the presence of ciproﬂoxacin (C) or
gemiﬂoxacin (G). Reaction mixtures were loaded and run on a
denaturing urea–8% polyacrylamide gel. Lanes 3 and 4 are treated
with ciproﬂoxacin and gemiﬂoxacin, respectively. Lanes 1 are controls
for non-treated DNA; lanes 2 and 5 are controls for DNA incubated
with the indicated enzyme without drugs. Lanes a, t, g and c are
marker lanes obtained by the dideoxynucleotide chain termination
method. Asterisk and division symbols indicate additional cleavage sites
around position 1.
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In the presence of the new oligo substrates, unique and
extremely strong cleavage bands corresponding to posi-
tion 1G of the consensus sequences were produced by
Topo IV and ﬂuoroquinolones (lanes 3 and 4, Figure 4A),
indicating that A/T at positions 4, 3 and +7, +8
in fact decrease DNA processing. In particular, the 1G
cut site was the most intense with both ﬂuoroquinolones in
the case of the wild-type consensus-derived oligo. In the
mutated sequences, gemiﬂoxacin-induced cleavage was
more prominent with GGAGGT and GGAGTG
sequences, while ciproﬂoxacin was more eﬃcient with
the GGATGG oligo (compare lanes 3 and 4, all oligo,
Figure 4A). Gemiﬂoxacin induced an extra band at
position +2 in oligos GGAGGG, GGAGGT and
GGATGG, respectively (lanes 4,  symbol, Figure 4A).
This cleavage site was particularly intense in the case of
oligo GGAGGT, where T, instead of G, is present at
position +2. An additional band was produced by
gemiﬂoxacin at position +5T in oligos GGAGGT and
GGATGG, respectively (lanes 4, U symbol, Figure 4A).
A few minor sites were present towards the DNA 30-end,
which were shared by all oligos.
When employing E. coli Gyr (Figure 4B), the results
were quite diﬀerent. Most strikingly, while cutting at
position 1G in the consensus sequence was still present;
this was not the most intense band along the DNA
sequence. As observed for Topo IV, the relative intensity
of strand scission at position 1 was higher in the wild-
type oligo (GGAGGG) compared to the mutant
sequences (lanes 3 and 4, Figure 4B). Ciproﬂoxacin-
induced cleavage was stronger than gemiﬂoxacin-
mediated breakage in the case of oligo GGAGGG and
GGATGG, while the reverse was found for oligos
GGAGGT and GGAGTG. Additional bands were
found both inside (downstream position 1) and outside
the consensus sequence (both upstream and downstream).
The wild-type oligo showed fewer cleavage bands inside
the consensus sequence.
The GGAGGGCCCTCC sequence adopts an A-like
guanine–guanine stacking in solution
Next, we wondered if the above described peculiar
consensus sequence could adopt a deﬁnite structure in
solution. It is reported that the DNA octamer
GGGGCCCC forms in aqueous solution a stable heter-
onomous DNA duplex where guanine–guanine stacking is
A-like, whereas cytosine bases stack in a B-like fashion
(30). To examine the actual conformation of the consensus
sequence primarily recognized by E. coli Topo IV
(Figure 4A), we compared the CD spectrum of our
sample1 oligo (GGAGGGCCCTCC), with that of the
reference oligo (GGGGCCCC) and of a control DNA
(GCGACGCGTCGC), which shares the same base
composition of the sample1 oligo, but displays a diﬀerent
sequence. In addition, sample1 oligo was compared to
sample2 oligo (ATAGGGCCCTAT) where ﬂanking
regions were A/T rich such as those used in the cleavage
assay of Figure 3. Under native conditions (T well below
Tm, i.e. 48C), the spectrum of the reference oligo exhibited
two strong overlapping positive bands at 285 nm and
at 260 nm, and a negative peak at 237 nm (Figure 5).
The CD of our sample1 oligo was essentially super-
imposable to the reference oligo, showing the same bands
with very similar intensities. Conversely, the control and
sample2 oligos displayed substantially diﬀerent CD
patterns with one positive band at 285 or 265 nm,
respectively, and a negative peak at 255 or 240 nm,
respectively. We conclude that the native consensus
sequence adopts in solution a peculiar conformation,
which closely resembles the heteronomous conformation
of the reference oligo [i.e. a combination of B-type and
A-type base stacking (30)], whereas the control sequence is
organized in a more classical B form. Sample2 oligo, on
turn, exhibits a spectrum which reﬂects a lower propensity
to adopt the heteronomous conformation thus favoring a
B form. This is in agreement with the shift of the CD
cross-over towards longer wavelength as an indication of
lower A-like character and with the crystal structure of the
dodecamer duplex CATGGGCCCATG showing a
structural continuum along the transition between
A- and B-DNA (31,32).
DISCUSSION
Type IIA DNA topoisomerases have concerted and
complementary functions in controlling bacterial chromo-
some topology: Gyr catalyzes the negative supercoiling
of closed-circular DNA, thus, it removes the positive
supercoils that arise during DNA unwinding; Topo IV
relaxes positive and negative supercoils, and unlinks
daughter chromosomes at cell division (33). In addition,
topoisomerases are crucial targets for ﬂuoroquinolone-
based therapy. In this instance, Gyr or Topo IV can be
alternative selective targets depending on the species
of origin: Gyr is often the primary target in Gram-
negative species, such as E. coli, while Topo IV is
principally aﬀected in Gram-positive species, such as
S. pneumoniae (14). However, it has also been reported
that topo IV and/or gyrase can be alternative intracellular
target depending on quinolone structure (34,35).
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Figure 5. CD spectra of sample1 oligo GGAGGGCCCTCC, sample2
oligo ATAGGGCCCTAT, reference oligo GGGGCCCCC and control
oligo GCGACGCGTCGC measured at 48C. Observed ellipticities were
converted to mean residue ellipticity [y]=deg cm2 dmol1 (Mol. Ellip.).
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To investigate whether this double biased behavior (Gyr
versus Topo IV and S. pneumoniae versus E. coli) could
arise from a distinctively speciﬁc recognition of DNA
sequences by topoisomerases ( quinolones), we compre-
hensively studied and compared the DNA sequence
speciﬁcity of Gyr and Topo IV from E. coli and
S. pneumoniae in the presence of clinically used ﬂuoro-
quinolones. In view of the key role played by these
proteins, the resulting information would be important
from both physiological and therapeutic standpoints.
A consensus sequence for the two topoisomerases from
S. pneumoniae has been recently reported using
S. pneumoniae ParE-ParC gene sequences as DNA
templates (19). Here, to impartially compare DNA
sequence speciﬁcity of enzymes from diﬀerent species,
we used non-speciﬁc DNA fragments derived from the
SV40 genome.
By statistical analysis of preferred bases around the
cleavage position (20/+20) of a large set of sites
(over 400), we found that the GGGCCC sequence at
positions 1/+5 was favored with both Gyr and Topo IV
from the two bacterial species considered. However, this
preference was much more prominent for the E. coli
enzymes. Conversely, positions 2 and +6 were
non-randomly selected only with S. pneumoniae enzymes,
which revealed a striking preference for A and T,
respectively.
Overall, statistical analysis of consensus sequences
reported no major diﬀerences between Topo IV and
Gyr, although the requirements for the latter appear to be
less stringent in the Gram-negative species. By contrast,
discrimination of Gram-positive and -negative enzymes
apparently resides on diﬀerent DNA sequence require-
ments for eﬃcient cleavage, in particular at positions 2
and +6.
The high structural similarity of the N-terminal binding
regions of ParC and GyrA from both S. pneumoniae and
E. coli species (36,37) may explain the comparable DNA
recognition properties shared by the tested topoisomerases
in the presence of the two quinolone drugs. As an added
proof, the aminoacidic residues reported to be essential in
the protein catalytic activity and implicated in quinolone
resistance, hence, likely involved in the concurrent binding
of topoisomerases to DNA and quinolones in the cleavage
complex (i.e. Arg32, Arg47, His78, His80, Ser83 and Asp/
Glu87 in E. coli GyrA and corresponding positions in
the other topoisomerases) (38–40), are identical in the
four tested enzymes. It is intriguing to note that the only
consistent diﬀerence in the aminoacidic sequence between
E. coli and S. pnemoniae N-terminal region of GyrA/ParC
subunits is at position 84 of E. coli GyrA
(and corresponding positions in the other enzymes),
where an Ala is substituted with a Ser in the Gram-
positive proteins. Since position 84 is just adjacent to other
positions involved in enzyme/quinolone/DNA interac-
tions (see above), it could be speculated that
the introduction of an H-bond donor site (i.e. Ser)
modulates S. pneumoniae topoisomerases DNA recogni-
tion properties, driving sequence speciﬁcity towards A/T
at positions 2/+6.
The ﬂuoroquinolone chemical nature did not play
a major role in determining the consensus sequence, at
least for the tested compounds. However, it inﬂuenced the
extent of cleavage stimulation. In particular, sites number
was similar between ciproﬂoxacin and gemiﬂoxacin with
E. coli enzymes, while it was clearly in favor of
gemiﬂoxacin with S. pneumoniae proteins. These results
are in line with the reported activity of the two drugs on
bacterial species: gemiﬂoxacin is more eﬀective than
ciproﬂoxacin on S. pneumoniae strains, while the activity
of the two drugs is similar on E. coli bacteria (41,42).
Therefore, our data indicate that, from a pharmacody-
namic point of view, the biased activity of the two drugs
may rest on their diﬀerent ability to poison the molecular
target, rather than on recognizing a diﬀerent sequence
determinant. This implies that DNA recognition is
initially driven by the topoisomerases and then modulated
by quinolone stabilization of the cleavage complex.
Our data, performed on SV40 DNA template, diﬀer
slightly from those obtained previously with the
S. pneumoniae genome DNA template (19). In the ﬁrst
report, the consensus found between positions 4 and +8
were GGANGNNCNTNC and GGAGGNNCNTNC,
asterisk at the cleavage site, for Topo IV and Gyr,
respectively (19), compared to NNANGNCCCTNN and
NNAGGNCCCTNN, respectively, in the present work.
Noteworthy, several preferences match exactly, whereas
others are not observed in one case or the other.
This diﬀerence depends in part on the level of statistical
stringency considered: on lowering the LogP threshold,
+2G and +3C bases become preferred in (19) and 4G,
3G and +8C register as slightly preferred with both
Gram-positive and -negative enzymes in this work
(Figure 2B and C). The combination of diﬀerent DNA
template, enzyme activity and drug concentration could be
responsible for the diverse statistical relevance found.
In fact, DNA traits consisting of two or more bases can be
diﬀerently represented within nucleic acids from various
origins. For instance, even though SV40 and ParC/ParE
DNAs share similar base composition (G/C percentage is
40% in SV40 and 42% in S. pneumoniae), GGG and CCC
sequences are 27% more frequent in the SV40 genome
than in the ParC/ParE genes.
Since each position is independently taken into account
during statistical analysis, we next analyzed E. coli
topoisomerase–quinolone cleavage eﬃciency on the full
DNA consensus sequences found in this work or obtained
by combining data from the present and previous research
(19). Further, mutations at selected preferred positions
were also introduced to determine the contribution of each
site on the cleavage complex DNA processivity.
We found that the 2/+6 consensus sequence
AGGGCCCT environed in G/C-, but not A/T-, rich
ﬂanking regions, is able to induce highly eﬃcient DNA
cleavage. In fact, the 8-nt long tract AGGGCCCT at
positions 2/+6, environed in an A/T-rich region, was
able to promote only weak DNA damage (Figure 3).
In this instance, cleavage intensity was similar among the
two enzymes and the two quinolones employed. In
contrast, addition of G and C bases at positions 4, 3
and +7, +8, respectively (19), signiﬁcantly augmented
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cleavage, especially with Topo IV (see Figure 4A and B).
The presence of the full consensus sequence was still
required: in fact, modiﬁcation of a single G nucleotide in
the 1/+5 region generally decreased cleavage, in the
same manner for Topo IV and Gyr. In addition, whereas
the intensity of cleavage with the wild-type sequence was
similar between ciproﬂoxacin and gemiﬂoxacin, diﬀer-
ences in cutting eﬃciency were observed at the mutated
sequences with the two ﬂuoroquinolones. In particular,
positions inside the 4-base staggered break seem primarily
implicated in quinolone binding. In fact, changes at
positions +2, +3 and +1, +4 more dramatically
impaired ciproﬂoxacin activity, whereas gemiﬂoxacin
was more severely aﬀected by nucleotide changes at +1
and +5. Therefore, gemiﬂoxacin requirements seem to be
somewhat less stringent than those of ciproﬂoxacin when
modifying the quinolone-interacting region of the con-
sensus sequence. These results are also supported by
reports showing an increased binding ability of quinolones
to Gn/Cn-rich sequences (43) and site-speciﬁc analysis of
E. coli Gyr with oxolinic acid (21).
Our data further suggest that positions 4, 3 and +7,
+8, which must be G/C rich, are likely required for
eﬃcient DNA recognition and binding by the topoisome-
rases, since these positions signiﬁcantly aﬀect cutting
intensity depending upon the enzyme, but not upon the
drug. The consensus found is particularly eﬀective for
Topo IV, less so in the case of gyrase, for which additional
features outside positions 4/+8 might play a key role in
speciﬁcity. Positions 2 and +6 are also probably
involved in enzyme recognition. In particular, they help
discriminate between proteins from diﬀerent bacterial
sources (e.g. S. pneumoniae versus E. coli), but not
between the two topoisomerases (see above).
Symmetry is an additional feature required for eﬃcient
DNA processing, as proven by analyzing cleavage sites on
the two complementary DNA strands and by testing
symmetric and non-symmetric consensus sequences.
This property reasonably arises from the dyadic symmetry
of topoisomerase complexes.
The consensus primary sequence found is very peculiar.
It is known that selected nucleic acid sequences can confer
unusual 3D characteristics to the DNA (29,44). Indeed,
it is reported that Gn/Cn DNA sequences can be
crystallized in A/B intermediate conformations (32).
More interestingly, the GGGGCCCC sequence adopts a
partial A-like structure in aqueous solution. In particular,
G bases are stacked in a DNA-A form, whereas the Cs
maintain a canonical B-form (30). Surprisingly, in the
reverse sequence CCCCGGGG, both C and G bases fold
in a diﬀerent A-like and less stable fashion (45).
By circular dichroism analysis, we proved that our
consensus sequence GGAGGGCCCTCC folds as the
reference GGGGCCCC DNA. A partial A-like confor-
mation is likely to protect G/C-rich regions, which are
involved in regulating transcription of many human genes
(46), against mutations: in fact these are mutated much
less than A/T-rich regions (47). According to our ﬁndings,
this particular A/B DNA conformation could also prompt
DNA recognition by topoisomerases. It should be noted
that the reverse sequence CCCCGGGG, which folds up
in a full-A-like structure and hence presents a diﬀerent
environment for enzyme recognition, was not selected by
statistical analysis of cleavage sites. Topoisomerases
would likely recognize 4, 3, 2 and +6, +7, +8nt,
permitting cleavage at 1 and +5 positions. Quinolones
would then be able to bind between the two loose ends
with subsequent inhibition of the enzymatic DNA
resealing.
Finally, our DNA speciﬁcity results using the test
quinolones suggest that the therapeutic eﬃcacy against a
bacterial species should be related to the frequency of
occurrence of Gn/Cn-rich sequences in the bacterial
genome and to the eﬃciency of cleavage complex
stabilization by the drug. Clearly, the observed clinical
outcome is also expected to depend upon the ADME
properties of each individual quinolone.
In summary, this work provided evidence that (i) a
symmetric Gn/Cn consensus sequence at positions 1/+5
allows eﬃcient bacterial topoisomerase-mediated DNA
processing; (ii) G/C over A/T-rich ﬂanking sequences
(positions 4, 3 and +7, +8) are highly preferred in
protein DNA processing, which is particularly eﬃcient for
Topo IV; (iii) positions 2 and +6 interact with the
enzyme and distinguish S. pneumoniae from E. coli
topoisomerases; (iv) positions 1 to +5 participate to
drug activity and may modulate cleavage intensity based
on the quinolone chemical nature; (v) symmetry of the
target sequence is a key trait to promote eﬀective cleavage
and (vi) the consensus sequence adopts a heteronomous
A/B conformation, which may trigger eﬃcient DNA
processing by enzyme/drug complex.
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